Golden State Equity Partners Increases Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Golden State Equity Partners boosted its position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 2,592.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 325,684 shares of the biopharmaceutical company's stock after purchasing an additional 313,587 shares during the period. Golden State Equity Partners owned about 0.16% of Sangamo Therapeutics worth $332,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Shelton Wealth Management LLC purchased a new stake in shares of Sangamo Therapeutics in the 4th quarter worth $29,000. Virtu Financial LLC purchased a new stake in Sangamo Therapeutics in the third quarter worth about $150,000. Geode Capital Management LLC raised its stake in shares of Sangamo Therapeutics by 14.6% in the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company's stock worth $1,853,000 after buying an additional 272,123 shares during the period. XTX Topco Ltd lifted its position in shares of Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company's stock valued at $90,000 after buying an additional 64,981 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Sangamo Therapeutics by 28.0% during the 3rd quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company's stock valued at $576,000 after acquiring an additional 145,400 shares during the period. 56.93% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on SGMO shares. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research report on Monday, January 27th. Jefferies Financial Group dropped their target price on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating for the company in a report on Tuesday, December 31st. Truist Financial lowered their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a research report on Thursday, January 23rd. Barclays upped their price objective on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an "overweight" rating in a research note on Thursday, November 14th. Finally, StockNews.com downgraded Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, December 24th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Sangamo Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $5.17.

Sangamo Therapeutics Price Performance

Shares of SGMO stock traded down $0.12 during trading hours on Friday, hitting $1.15. The stock had a trading volume of 5,626,569 shares, compared to its average volume of 5,598,266. The stock's 50-day moving average price is $1.63 and its two-hundred day moving average price is $1.37. Sangamo Therapeutics, Inc. has a one year low of $0.30 and a one year high of $3.18. The stock has a market capitalization of $239.94 million, a price-to-earnings ratio of -1.53 and a beta of 1.30.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The business had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. During the same quarter in the previous year, the company posted ($0.34) EPS. As a group, equities research analysts predict that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.